Navigation Links
New Oral Drugs Hailed for Treating MS
Date:1/31/2011

By Dennis Thompson
HealthDay Reporter

MONDAY, Jan. 31 (HealthDay News) -- For decades, research into treatments for multiple sclerosis has plodded forward, making slow but significant gains in improving the lives of people with the degenerative nerve disorder.

That steady but slow pace made the speed at which progress occurred in the past year nearly breathtaking, with the U.S. Food and Drug Administration approving a number of new breakthrough drugs for people with MS.

Nicholas LaRocca, vice president of health-care delivery and policy research for the National Multiple Sclerosis Society, said that 2010 was "an unprecedented year for MS, both in terms of the many developments that are in the pipeline as well as drugs that have come to market."

The new medications broke new ground not only through the therapy they provide but also in the way they are administered. The drugs can be taken orally, a break from past MS treatments that had to be given by either injection or IV.

They include:

  • Gilenya (fingolimod), the first oral medication designed to reduce relapses and delay the progression of MS.
  • Ampyra (dalfampridine), the first drug approved to treat a specific symptom of MS -- in this case, improving people's ability to walk.
  • Nuedexta, a two-drug combination designed to treat people with MS who have lost emotional control because of a symptom known as pseudobulbar affect, a severe emotional consequence of the disorder that causes uncontrollable laughing or crying.

Other oral therapies are in the pipeline. One now under FDA review is cladribine, a drug aimed at reducing relapses that could further improve convenience for people with MS, LaRocca said.

"It is taken orally but in discrete blocks of time over the course of the year," he said. "It's a couple of very short courses of oral therapy, as opposed to taking it constantly."

LaRocca said that these and other new drugs that have hit the market or on the verge of FDA approval will make it much easier for those with MS to find relief.

"People respond differently to different therapies," he said. "The more treatments we have, the higher the likelihood that a person will find a treatment that works best for them. We're going to see a steady stream of options for people with MS, providing people with the choices they need."

The new oral therapies also help people regain some small sense of control by allowing them to more easily take their medications, said Dr. Ron Cohen, chief executive and founder of Acorda Therapeutics, the company that developed Ampyra.

"It's certainly a more convenient form of the type of therapy that's already been available as an injection," Cohen said. "What's not known right now is, of all the orals, the relative efficacy of these orals versus the best of the injectables. With the injectables, there's a pretty good sense of what to expect in terms of efficacy and safety. It will take several years to develop such a track record for oral medications."

With the approval of the new drugs, eyes are turning toward the future and the next potential advance in MS treatment. Both Cohen and LaRocca said that treatments that repair the neural damage caused by multiple sclerosis are the next frontier for researchers.

Multiple sclerosis is now believed to be an autoimmune disorder in which the body damages the nervous system by attacking myelin, the fatty substance that surrounds and protects nerve fibers, according to the National Multiple Sclerosis Society.

The drug Ampyra works by restoring the conductive power of nerves that have lost their myelin, Cohen said.

"Right now, there's nothing that can repair the damage once it's been done," he said. "If we had something that could restore the myelin, you could potentially dial back the damage done by the disease."

The National Multiple Sclerosis Society supports four research centers, two in the United States and two in the United Kingdom, that are focused on neural protection and repair, LaRocca said.

"We have drugs that can slow or stop the progression of MS," he said. "We don't have treatments that can repair the damage to the nervous system caused by MS. That's really the next frontier. That's what we hope to see in the pipeline in the future."

More information

The U.S. National Institute of Neurological Disorders and Stroke has more on multiple sclerosis.

SOURCES: Nicholas LaRocca, Ph.D., vice president, health-care delivery and policy research, National Multiple Sclerosis Society, New York City; Ron Cohen, M.D., chief executive, Acorda Therapeutics, Hawthorne, N.Y.


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Not All Heart Failure Drugs Boost Survival Equally
2. Epilepsy Drugs May Raise Fracture Risk in Older Adults
3. Drugs for hair loss and BPH may result in loss of libido, ED in men
4. Evidence lacking for widespread use of costly antipsychotic drugs, says Stanford researcher
5. Studies Decipher How Anti-Smoking Drugs Work
6. Structure of key molecule in immune system provides clues for designing drugs
7. Heartburn Drugs May Raise Pneumonia Risk
8. Trio of drugs may combat triple negative breast cancer
9. Drugs are safe, active in patients normally ineligible for clinical trial
10. Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
11. Economist honored for study on impact of new cancer drugs on life expectancy
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Oral Drugs Hailed for Treating MS 
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... provides business development, education, networking and recognition opportunities as well as advocacy for ... Works in Holmdel, NJ on February 23. The Council's Innovation Forecast event ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... and hearing disabilities, it is so critically important that we all are aware ... That is why Mediaplanet is proud to announce the launch of its newest ...
(Date:2/24/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... Yisrayl makes an astounding statement when he says that the entire Bible was written ... the current times so plainly that anyone should be able to see the time ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... into the Senior International Elite division on February 12th. Ms. Esparza qualified ... at the elite qualifier competition held in Las Vegas, Nevada. Frida is one ...
(Date:2/23/2017)... Miami, FL (PRWEB) , ... February 23, 2017 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – will return to the La Gorce Country Club in Miami Beach ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Australien, 24. Februar 2017 ITL ... Unternehmen des Gesundheitsbereiches, ist erfreut, für das zum ... dem entsprechenden Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. ... Aktualisierung zum Wachstum" finden Sie hier . ... Gewinn nach Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... 23, 2017  This report analyzes the worldwide markets ... Products: Intermediates, Analytical, and Others. The ... Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2022. Also, a six-year historic analysis is provided ...
(Date:2/24/2017)... 2017 Medivir AB (Nasdaq Stockholm: ... new Board of Directors that will be submitted to ... comprises representatives of the company,s three largest shareholders at ... have accepted a seat on the Nomination Committee, and ... 2016-2017 Nomination Committee was as follows:  ...
Breaking Medicine Technology: